schliessen

Filtern

 

Bibliotheken

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affinity ( K D ) of 504 nM, blocks Stat3–phospho-tyrosine (pTyr) peptide interactions and Stat3 activat... Full description

Journal Title: Proceedings of the National Academy of Sciences 12 June 2012, Vol.109(24), p.9623
Main Author: Xiaolei Zhang
Other Authors: Peibin Yue , Brent D. G. Page , Tianshu Li , Wei Zhao , Andrew T. Namanja , David Paladino , Jihe Zhao , Yuan Chen , Patrick T. Gunning , James Turkson
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0027-8424 ; E-ISSN: 1091-6490 ; DOI: 10.1073/pnas.1121606109
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: pnas_s109_24_9623
title: Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
format: Article
creator:
  • Xiaolei Zhang
  • Peibin Yue
  • Brent D. G. Page
  • Tianshu Li
  • Wei Zhao
  • Andrew T. Namanja
  • David Paladino
  • Jihe Zhao
  • Yuan Chen
  • Patrick T. Gunning
  • James Turkson
subjects:
  • Sciences (General)
ispartof: Proceedings of the National Academy of Sciences, 12 June 2012, Vol.109(24), p.9623
description: Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affinity ( K D ) of 504 nM, blocks Stat3–phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4–6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102–mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion. Treatment of breast cancer cells with BP-1-102 further blocks Stat3–NF-κB cross-talk, the release of granulocyte colony-stimulating factor, soluble intercellular adhesion molecule 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression. Intravenous or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.
language: eng
source:
identifier: ISSN: 0027-8424 ; E-ISSN: 1091-6490 ; DOI: 10.1073/pnas.1121606109
fulltext: fulltext_linktorsrc
issn:
  • 0027-8424
  • 00278424
  • 1091-6490
  • 10916490
url: Link


@attributes
ID1601978639
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid109_24_9623
sourceidpnas_s
recordidTN_pnas_s109_24_9623
sourcesystemPC
dbid
0PNE
1RNA
pqid1020566935
galeid295441176
display
typearticle
titleOrally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
creatorXiaolei Zhang ; Peibin Yue ; Brent D. G. Page ; Tianshu Li ; Wei Zhao ; Andrew T. Namanja ; David Paladino ; Jihe Zhao ; Yuan Chen ; Patrick T. Gunning ; James Turkson
ispartofProceedings of the National Academy of Sciences, 12 June 2012, Vol.109(24), p.9623
identifier
subjectSciences (General)
descriptionComputer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affinity ( K D ) of 504 nM, blocks Stat3–phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4–6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102–mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion. Treatment of breast cancer cells with BP-1-102 further blocks Stat3–NF-κB cross-talk, the release of granulocyte colony-stimulating factor, soluble intercellular adhesion molecule 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression. Intravenous or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.
languageeng
source
version10
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttp://www.pnas.org/content/109/24/9623.abstract$$EView_full_text_in_National_Academy_of_Sciences_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Xiaolei Zhang
1Peibin Yue
2Brent D. G. Page
3Tianshu Li
4Wei Zhao
5Andrew T. Namanja
6David Paladino
7Jihe Zhao
8Yuan Chen
9Patrick T. Gunning
10James Turkson
titleOrally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
description

Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affinity ( K D ) of 504 nM, blocks Stat3–phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4–6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102–mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion. Treatment of breast cancer cells with BP-1-102 further blocks Stat3–NF-κB cross-talk, the release of granulocyte colony-stimulating factor, soluble intercellular adhesion molecule 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression. Intravenous or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.

subjectSciences (General)
general
0English
1National Acad Sciences
210.1073/pnas.1121606109
3PNAS (National Academy of Sciences)
4National Academy of Sciences (U.S.)
sourceidpnas_s
recordidpnas_s109_24_9623
issn
00027-8424
100278424
21091-6490
310916490
rsrctypearticle
creationdate2012
addtitleProceedings of the National Academy of Sciences
searchscope
0pnas_full
1pnas4
2pnas5
scope
0pnas_full
1pnas4
2pnas5
lsr45$$EView_full_text_in_National_Academy_of_Sciences_(Access_to_full_text_may_be_restricted)
tmp01
0PNAS (National Academy of Sciences)
1National Academy of Sciences (U.S.)
tmp02
0PNE
1RNA
startdate20120612
enddate20120612
lsr40Proceedings of the National Academy of Sciences, 12 June 2012, Vol.109 (24), p.9623
doi10.1073/pnas.1121606109
citationpf 9623 vol 109 issue 24
lsr30VSR-Enriched:[pages, pqid, galeid]
sort
titleOrally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
authorXiaolei Zhang ; Peibin Yue ; Brent D. G. Page ; Tianshu Li ; Wei Zhao ; Andrew T. Namanja ; David Paladino ; Jihe Zhao ; Yuan Chen ; Patrick T. Gunning ; James Turkson
creationdate20120612
lso0120120612
facets
frbrgroupid7100463996099647423
frbrtype5
newrecords20190724
languageeng
topicSciences (General)
collection
0PNAS (National Academy of Sciences)
1National Academy of Sciences (U.S.)
prefilterarticles
rsrctypearticles
creatorcontrib
0Xiaolei Zhang
1Peibin Yue
2Brent D. G. Page
3Tianshu Li
4Wei Zhao
5Andrew T. Namanja
6David Paladino
7Jihe Zhao
8Yuan Chen
9Patrick T. Gunning
10James Turkson
jtitleProceedings of the National Academy of Sciences
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
au
0Xiaolei Zhang
1Peibin Yue
2Brent D. G. Page
3Tianshu Li
4Wei Zhao
5Andrew T. Namanja
6David Paladino
7Jihe Zhao
8Yuan Chen
9Patrick T. Gunning
10James Turkson
atitleOrally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
jtitleProceedings of the National Academy of Sciences
risdate20120612
volume109
issue24
spage9623
issn0027-8424
eissn1091-6490
formatjournal
genrearticle
ristypeJOUR
abstract

Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an affinity ( K D ) of 504 nM, blocks Stat3–phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4–6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102–mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion. Treatment of breast cancer cells with BP-1-102 further blocks Stat3–NF-κB cross-talk, the release of granulocyte colony-stimulating factor, soluble intercellular adhesion molecule 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression. Intravenous or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.

pubNational Acad Sciences
doi10.1073/pnas.1121606109
urlhttp://www.pnas.org/content/109/24/9623.abstract
lad01Proceedings of the National Academy of Sciences
pages9623-9628
date2012-06-12